Reason for request
Re-assessment of the actual benefit of third-generation oral contraceptives in response to a request by the Directorate-General for Health dated 27 December 2011.
Clinical Benefit
| Insufficient |
taking into account both the increased risk of venous thromboembolic events and the lack of demonstrated benefit in terms of clinical safety in women exposed to third-generation oral contraceptives compared with second- or first-generation oral contraceptives, the actual benefit of these proprietarymedicinal products must be regarded as insufficient for reimbursement by National Health Insurance.
|
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
2sge5pwDqbCe2HMy